Drug interactions
Metformin-repaglinide + Ritlecitinib
Severity: Moderate
Metformin-repaglinide and Ritlecitinib: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Ritlecitinib may inhibit CYP3A4 and raise exposure to repaglinide, a CYP3A4 and CYP2C8 substrate. Higher repaglinide levels can increase the risk of hypoglycemia.
What this interaction means in plain words
Metformin-repaglinide and Ritlecitinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Metformin-repaglinide belongs to Endocrine; Ritlecitinib belongs to Oncology.
Why it happens
Inhibition of intestinal and hepatic CYP3A4 reduces repaglinide metabolism.
What to do
Monitor blood glucose when starting or stopping ritlecitinib. Reduce the repaglinide dose if hypoglycemia occurs.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Metformin-repaglinide and Ritlecitinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Metformin-repaglinide
Other interactions of Ritlecitinib
Frequently asked questions
Can I take Metformin-repaglinide with Ritlecitinib?
MediHelp rates the interaction as moderate. Metformin-repaglinide and Ritlecitinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Ritlecitinib may inhibit CYP3A4 and raise exposure to repaglinide, a CYP3A4 and CYP2C8 substrate. Higher repaglinide levels can increase the risk of hypoglycemia.
How serious is the interaction between Metformin-repaglinide and Ritlecitinib?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor blood glucose when starting or stopping ritlecitinib. Reduce the repaglinide dose if hypoglycemia occurs.
What other medicines interact with Metformin-repaglinide?
MediHelp also lists interactions of Metformin-repaglinide with, for example, Gemfibrozil, Apalutamide, Clarithromycin. The full list is on the Metformin-repaglinide page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
